Amanda Mathis
Overview
Explore the profile of Amanda Mathis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
342
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mathis A, Sale M, Cornpropst M, Sheridan W, Ma S
Clin Transl Sci
. 2022 Feb;
15(4):1027-1035.
PMID: 35212456
Hereditary angioedema (HAE) is an autosomal dominant disorder characterized by recurrent episodes of swelling of the skin, larynx, gastrointestinal tract, genitals, and extremities that can be disruptive to patient quality...
2.
Mathis A, Collins D, Dobo S, Walling D, Sheridan W, Taylor R
Clin Pharmacol Drug Dev
. 2022 Feb;
11(4):467-474.
PMID: 35182042
Galidesivir (BCX4430) is an adenosine nucleoside analog broadly active in cell culture against multiple RNA virus families, and active in animal models of viral diseases associated with Ebola, Marburg, yellow...
3.
Taylor R, Bowen R, Demarest J, DeSpirito M, Hartwig A, Bielefeldt-Ohmann H, et al.
Viruses
. 2022 Jan;
14(1).
PMID: 35062212
Coronavirus disease 2019 (COVID-19) has claimed the lives of millions of people worldwide since it first emerged. The impact of the COVID-19 pandemic on public health and the global economy...
4.
Julander J, Demarest J, Taylor R, Gowen B, Walling D, Mathis A, et al.
Antiviral Res
. 2021 Sep;
195:105180.
PMID: 34551346
Galidesivir (BCX4430) is an adenosine nucleoside analog that is broadly active in cell culture against several RNA viruses of various families. This activity has also been shown in animal models...
5.
Peric M, Pesic D, Alihodzic S, Fajdetic A, Herreros E, Gamo F, et al.
Br J Pharmacol
. 2020 Oct;
178(2):363-377.
PMID: 33085774
Background And Purpose: Efficacy of current antimalarial treatments is declining as a result of increasing antimalarial drug resistance, so new and potent antimalarial drugs are urgently needed. Azithromycin, an azalide...
6.
Lim S, Osuna C, Best K, Taylor R, Chen E, Yoon G, et al.
Sci Transl Med
. 2020 Jun;
12(547).
PMID: 32522808
Zika virus infection in humans has been associated with serious reproductive and neurological complications. At present, no protective antiviral drug treatment is available. Here, we describe the testing and evaluation...
7.
Chong P, Shotwell J, Miller J, Price D, Maynard A, Voitenleitner C, et al.
J Med Chem
. 2019 Feb;
62(7):3254-3267.
PMID: 30763090
We previously described the discovery of GSK5852 (1), a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV), in which an N-benzyl boronic acid was essential for potent antiviral activity....
8.
Westover J, Mathis A, Taylor R, Wandersee L, Bailey K, Sefing E, et al.
Antiviral Res
. 2018 Jun;
156:38-45.
PMID: 29864447
Rift Valley fever virus (RVFV) is a mosquito-borne pathogen endemic to sub-Saharan Africa and the Arabian Peninsula. There are no approved antiviral therapies or vaccines available to treat or prevent...
9.
Wilfret D, Walker J, Voitenleitner C, Baptiste-Brown S, Lovern M, Kim J, et al.
Clin Pharmacol Drug Dev
. 2016 Apr;
3(6):439-48.
PMID: 27129119
This first-time-in-human, randomized, double-blind, placebo-controlled, dose-escalation study assessed the safety, tolerability, pharmacokinetics, and antiviral activity of GSK2485852, a hepatitis C virus (HCV) NS5B inhibitor, in 27 chronically infected HCV genotype-1...
10.
Pouliot J, Thomson M, Xie M, Horton J, Johnson J, Krull D, et al.
Antimicrob Agents Chemother
. 2015 Aug;
59(10):6539-50.
PMID: 26259798
The hepatitis C virus (HCV) NS4B protein is an antiviral therapeutic target for which small-molecule inhibitors have not been shown to exhibit in vivo efficacy. We describe here the in...